Custom Monoclonal Antibody Production Services

Monoclonal antibodies (mAbs) are highly specific immunoglobulins derived from a single B-cell clone. They are widely used in research and assay development due to their ability to recognize defined epitopes with high specificity.

Common monoclonal antibody discovery platforms include:

• Hybridoma technology (classical in vivo approach)
• Phage display (in vitro library-based selection)
• Single B-cell technologies (FACS and microfluidics-based systems)

Each platform offers distinct advantages depending on antigen properties, timeline, and downstream application.

At AbTriva, we provide flexible monoclonal antibody development solutions tailored to different research needs:

• End-to-end antibody development or modular services
• Multiple discovery platforms to match target complexity
• Support for applications such as WB, ELISA, IHC, and flow cytometry
• Scalable production from early discovery to preclinical research

In addition to custom services, we maintain a growing portfolio of in-stock monoclonal antibodies covering a wide range of targets for immediate use.

Production Platforms

We offer multiple monoclonal antibody discovery platforms, allowing researchers to select the most appropriate approach based on target type, application, and timeline.

Platform	Best For	Key Advantages
Hybridoma Development Platform	Standard immunogenic proteins	Well-established method, stable monoclonal cell lines, cost-effective
Phage Display Platform	Toxic, non-immunogenic, or highly conserved targets	In vitro selection, large library diversity, no need for animal immunization
FACS Single B Cell Sorting Platform	Rapid identification of antigen-specific B cells	High-throughput sorting of memory B cells, efficient early-stage screening
Beacon Single B Cell Platform	Functional antibody discovery and characterization	Microfluidics-based system enabling real-time analysis of antibody secretion, binding, and functional activity

Platform selection matters.
FACS-based methods rely on flow cytometry to isolate antigen-binding B cells, while Beacon technology uses microfluidics to screen antibody-secreting cells at the single-cell level with functional readouts. In many projects, combining platforms can improve discovery efficiency and reduce bias.

Popular Monoclonal Antibody Development Services

We offer both end-to-end solutions and modular services depending on your project requirements.

Full-Service Antibody Development

• Antigen design and preparation (peptide or recombinant protein)
• Animal immunization and immune response monitoring
• Hybridoma generation or single B-cell isolation
• Screening and clone selection
• Antibody expression and purification
• Basic validation and QC

Standalone Services

• Antigen design and synthesis
• Immunization services
• Hybridoma screening and subcloning
• Recombinant antibody expression (CHO, HEK293)
• Antibody purification

Advanced Engineering Services

• Antibody humanization
• Affinity maturation
• Epitope mapping
• Isotype switching and subclass engineering

These services can be combined or customized depending on your workflow and experimental goals.

Applications & Use Cases

Our monoclonal antibodies can be developed to support a wide range of research and assay applications, including:

• Western blot (WB)
• Enzyme-linked immunosorbent assay (ELISA)
• Immunohistochemistry (IHC)
• Immunocytochemistry (ICC)
• Flow cytometry
• Immunoprecipitation (IP)
• Functional blocking or neutralization assays

Application-specific validation is not performed by default for all assays.

Validation strategies are defined based on your project requirements, target characteristics, and intended downstream use. Relevant assays can be incorporated into the workflow upon request.

Overview of the Workflow

Phase	Service	Description	Deliverables	Timeline
Phase 1	Antigen Preparation	Design and production of peptide or recombinant antigen	Antigen material, design report	1–3 weeks
Phase 2	Immunization & Library Generation	Animal immunization and immune response monitoring	Serum samples, titer data	4–8 weeks
Phase 3	Screening & Clone Selection	Hybridoma screening or single B-cell selection	Candidate clones, screening data	2–4 weeks
Phase 4	Expression & Production	Small-scale expression and scale-up in mammalian systems	Purified antibody (mg scale)	2–3 weeks
Phase 5	Purification & QC	Affinity purification and analytical testing	QC report, purified antibody	1–2 weeks

Typical total timeline: ~8–16 weeks
Timelines may vary depending on antigen complexity, platform selection, and screening outcomes.

Quality & Validation

We focus on delivering antibodies that are experimentally useful and reproducible.

Standard Quality Control

• Purity assessment (SDS-PAGE)
• Binding validation (ELISA or equivalent)

Optional Advanced Characterization

• Application-specific testing (e.g., WB, IHC, flow cytometry, if required)
• Affinity measurement (SPR or BLI)
• Epitope binning or mapping
• Cross-reactivity assessment

Validation strategies are tailored based on your intended application.

Why Researchers Choose AbTriva

• Multi-platform capability
  Access to hybridoma, phage display, and single B-cell technologies in one workflow
• Scientist-led project design
  Feasibility assessments based on antigen properties and experimental goals
• Flexible service structure
  Full-service development or modular project support
• Transparent timelines and checkpoints
  Clear communication at each stage of the project
• Application-focused development
  Antibodies developed with downstream use in mind, not just production

We do not assume universal success across all targets. Antibody development outcomes depend on factors such as antigen design, immunogenicity, and screening performance. Our team works to optimize conditions and provide realistic expectations from the outset.

Start Your Project

Whether you are developing a new antibody for a specific assay or scaling up an existing clone, we can help design a workflow aligned with your research goals.

• Request a quote based on your target and application
• Consult with our scientific team to select the appropriate platform
• Submit antigen sequences or project details for evaluation

Typical response time: 1–2 business days

Contact us to discuss your monoclonal antibody development needs.